Cat. No. | Product Name | Target | Signaling Pathways |
---|---|---|---|
T1992 |
Mertansine
DM1,Maytansinoid DM1 |
Microtubule Associated | Cytoskeletal Signaling |
Mertansine (DM1) 是一种微管蛋白抑制剂,也是一种抗体可缀合的美登木素生物碱。它通过连接体连接到单克隆抗体上,形成抗体偶联药物。 | |||
T76939 | Cantuzumab mertansine | ||
Cantuzumab mertansine (SB-408075; huC242-DM1) 是一种ADC,是强效美登素衍生物 (DM1) 和针对 CanAg 的人源化单克隆抗体 (huC242) 的免疫偶联物。Cantuzumab mertansine 对结肠癌细胞具有细胞毒性,并且对一系列 CanAg 阳性人肿瘤异种移植物具有广泛的抗肿瘤活性。 | |||
T77406 |
lorvotuzumab
|
Others | Others |
Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) 是一种人源化结合 CD56 (NCAM1) 的单克隆抗体。Lorvotuzumab 可用于合成抗体-药物偶联物( Lorvotuzumab mertansine)。 | |||
T18678 |
SC-VC-PAB-DM1
|
Others | Others |
SC-VC-PAB-DM1 is a drug-linker conjugate utilized in Antibody-Drug Conjugates (ADC), featuring DM1 (Mertansine, a tubulin inhibitor) linked through the SC-VC-PAB[1] ADC linker to deliver potent antitumor activity. | |||
T77911 |
Cantuzumab
|
||
Cantuzumab是一种针对CanAg抗原的单克隆抗体。它能与多种细胞毒性分子结合,形成抗体-活性分子偶联物(ADC),例如Cantuzumab mertansine和Cantuzumab ravtansine。 | |||
T17793 |
DBCO-PEG4-Ahx-DM1
|
Others | Others |
DBCO-PEG4-Ahx-DM1 is a drug-linker conjugate that combines the microtubulin inhibitor DM1 (mertansine), which is an antibody-conjugatable maytansinoid designed to reduce systemic toxicity and improve tumor-specific delivery, with the linker DBCO-PEG4-Ahx, for the development of antibody drug conjugates (ADCs). | |||
T80217 |
BT1718
|
MMP | Proteases/Proteasome |
BT1718是一种针对MT1-MMP的双功能抗癌肽,通过MT1-MMP靶向肿瘤来传递细胞毒性有效载荷Mertansine。作为一种多肽-毒素偶联物,其KD值为3 nM。MT1-MMP在多种晚期实体肿瘤如三阴性乳腺癌(TNBC)和非小细胞肺癌中呈现过表达。 | |||
T17832 |
DM1-PEG4-DBCO
|
Others | Others |
DM1-(PEG)4-DBCO is a drug-linker conjugate that combines the potent microtubulin inhibitor mertansine (DM1) with the DBCO-PEG4-Ahx linker for the development of antibody-drug conjugates (ADCs). This conjugation aims to mitigate the systemic toxicity associated with maytansine while improving tumor-specific delivery, leveraging DM1’s capabilities as an antibody-conjugatable maytansinoid. |